With proprietary treatments and an internationally-acclaimed management, Clearmind Medicine is set to revolutionise how we heal.Join Us
With a clear focus on alcohol abuse and binge drinking, Clearmind's first drug candidate addresses very common (and costly) afflictions which to date, have limited solutions.
Clearmind’s Chief Scientific Officer is a prolific inventor of international acclaim. Pair that with a proven leader in the pharmaceutical space and you have a powerful combination.
Clearmind focuses exclusively on IP-protected treatments. With granted patents in the U.S and EP, allowed CN application and a nearly allowed IN application, Clearmind is set to establish its own territory in a competitive space.
MEAI holds the promise to break the binge-drinking vicious cycle by potentially innervating neural pathways such as 5-HT1A which leads to “sensible behavior”.
Pre-clinical in vivo results demonstrate longtail tapering off of activity via oral administration. This may explain the anecdotal reports on the self-limiting property of MEAI—unlike traditional treatments.
The literature shows that 5-HT1A receptors are associated with controlling craving behaviour across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.
Alchohol Use Disorder
MEAI shows promise for Alcohol Use Disorder, in which an individual cannot limit their alcohol intake despite negative consequences.
MEAI may also be used for binge drinking (described as 4 or more drinks in about 2 hours). 1 in 6 adults binge drink once a week in the US.
The information contained in this table is provided as of March 1, 2021 and is provided solely for the reader's general knowledge and is not intended to be a comprehensive review of all matters and developments concerning the companies listed. Clearmind Medicine makes no warranties or representations as to the accuracy of such information. The information provided on this table is not a substitute for independent professional advice before making any investment decisions. We strongly encourage you to review the continuous disclosure record of each of these companies available at www.sedar.com and sec.gov/edgar for a complete and up to date description of their respective businesses.
Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.
Oded Gilboa has over 23 years of experience in finance and public accounting, having served as a senior finance executive in the technology and biotech industries with responsibilities in corporate finance, accounting, strategic planning and operational and financial management. He holds a B.A in Economics and Accounting degree from Tel-Aviv University and an M.B.A. from Recanati Business School at Tel-Aviv University.
Oz Locker is a business entrepreneur with over a decade of managerial and operational experience.
Most recently, Mr. Locker served as the CEO of a vertically integrated cannabis company. Prior, he held various executive business and operational roles in fast growing technological startups.
He holds an MBA from Harvard Business School.
Prof. Haden is a trailblazer in the field pf psychedelic medicine, currently serving as Director of Clinical Research at Psygen and Adjunct Professor at the University of British Columbia School of Population and Public Health, and was a co-founder and spent 10 years as Executive Director of the renown Multidisciplinary Association for Psychedelic Studies Canada (MAPS). Haden has dedicated the last 30 years to public education and training on drugs and drug policy, including advising the Health Officers Council of British Columbia on the issues of a regulated market for all currently illegal drugs as well as working with Addiction Services in counseling and supervisory roles. He is a frequent keynote speaker and distinguished author on the issues of drug control policy and psychedelics and was awarded the Queen's Diamond Jubilee Medal for his work on drug policy reform in 2013.
Prof. Davidson has published over 350 articles in peer reviewed prestigious journals in the area of Psychiatry and of Alzheimer’s disease, including on development of novel treatments. Previously he was Department Chairman at the Tel Aviv University and Chief Editor of the European Neuropsychopharmacology journal. He is currently Chairman of the department of psychiatry at the Nicosia University medical school, the President of the Alzheimer Center in Israel, and actively involved in drug development.
Prof. Alon Friedman is Professor of Neuroscience at both Ben-Gurion University of the Negev (BGU) in Beersheba, Israel, and Dalhousie University, Halifax, Canada. He is best known for his discoveries of the link between blood–brain barrier dysfunction (BBBd) and neuropathologies, and the mechanisms underlying BBBd-related diseases. His team developed novel imaging modalities for the diagnosis of BBBd in neuro-psychiatric disorders.
Prof. Gal Yadid is an expert in neuropsychopharmacology, and is a Lab Chief in the Brain center of the Bar Ilan University. His field research and treatment development for reward-related psychiatric disorders, specifically Addiction, PTSD and depression. His research moved from preclinical (using unique animal models) to clinical applying various methods (behavioral, cognitive, histochemical, neurochemical, genetic / epigenetic, microbiome).
John Rewcastle has over 20 years of industry experience in clinical and regulatory affairs with an FDA specialization. He has worked collaboratively with the agency during all phases of the approval process including breakthrough designation application, clinical trial design, trial management, application submission, interactive review, panel presentation as well as post-approval trials. He has published extensively in the medial literature and has held adjunct professorships at the University of Calgary and the University of Southern California.